Cancers, Vol. 16, Pages 1403: Obesity and Inflammatory Factors in the Progression of Early-Onset Colorectal Cancer
Galandiuk
Metabolic dysfunction associated with obesity leads to a chronic pro-inflammatory state with systemic effects, including the alteration of macrophage metabolism. Tumor-associated macrophages have been linked to the formation of cancer through the production of metabolites such as itaconate. Itaconate downregulates peroxisome proliferator-activated receptor gamma as a tumor-suppressing factor and upregulates anti-inflammatory cytokines in M2-like macrophages. Similarly, leptin and adiponectin also influence macrophage cytokine expression and contribute to the progression of colorectal cancer via changes in gen...
Source: Cancers - April 3, 2024 Category: Cancer & Oncology Authors: Alexandra N. Jones Katharina M. Scheurlen Anne Macleod Hillary L. Simon Susan Galandiuk Tags: Review Source Type: research
Intestinal carcinogenicity screening of environmental pollutants using organoid-based cell transformation assay
Arch Toxicol. 2024 Apr 2. doi: 10.1007/s00204-024-03729-y. Online ahead of print.ABSTRACTThe high incidence of colorectal cancer (CRC) is closely associated with environmental pollutant exposure. To identify potential intestinal carcinogens, we developed a cell transformation assay (CTA) using mouse adult stem cell-derived intestinal organoids (mASC-IOs) and assessed the transformation potential on 14 representative chemicals, including Cd, iPb, Cr-VI, iAs-III, Zn, Cu, PFOS, BPA, MEHP, AOM, DMH, MNNG, aspirin, and metformin. We optimized the experimental protocol based on cytotoxicity, amplification, and colony formation o...
Source: Archives of Toxicology - April 2, 2024 Category: Toxicology Authors: Ziwei Wang Shen Chen Yuzhi Guo Rui Zhang Qi Zhang Xinhang Jiang Miao Li Yue Jiang Lizhu Ye Xiaoyu Guo Chuang Li Guangtong Zhang Daochuan Li Liping Chen Wen Chen Source Type: research
Intestinal carcinogenicity screening of environmental pollutants using organoid-based cell transformation assay
Arch Toxicol. 2024 Apr 2. doi: 10.1007/s00204-024-03729-y. Online ahead of print.ABSTRACTThe high incidence of colorectal cancer (CRC) is closely associated with environmental pollutant exposure. To identify potential intestinal carcinogens, we developed a cell transformation assay (CTA) using mouse adult stem cell-derived intestinal organoids (mASC-IOs) and assessed the transformation potential on 14 representative chemicals, including Cd, iPb, Cr-VI, iAs-III, Zn, Cu, PFOS, BPA, MEHP, AOM, DMH, MNNG, aspirin, and metformin. We optimized the experimental protocol based on cytotoxicity, amplification, and colony formation o...
Source: Archives of Toxicology - April 2, 2024 Category: Toxicology Authors: Ziwei Wang Shen Chen Yuzhi Guo Rui Zhang Qi Zhang Xinhang Jiang Miao Li Yue Jiang Lizhu Ye Xiaoyu Guo Chuang Li Guangtong Zhang Daochuan Li Liping Chen Wen Chen Source Type: research
Ergebnisse einer Umfrage zur aktuellen Behandlung der chronischen Rhinosinusitis mit nasalen Polypen
Laryngorhinootologie DOI: 10.1055/a-2246-2793
Einleitung Mit einer Prävalenz von 0,55–4% ist die chronische Rhinosinusitis mit nasalen Polypen (CRSwNP) ein relevanter Bestandteil der täglichen Arbeit in deutschen HNO-Kliniken. Ziel der Fragebogen-basierten Datenerhebung war es, den aktuellen Behandlungsstand der CRSwNP in deutschen Krankenhäusern zu erfassen.
Material und Methoden Hierzu erfolgte der Versand von 24 Fragen innerhalb eines anonymisierten Onlinefragenbogens an deutsche HNO-Kliniken.
Ergebnisse Von 160 angeschriebenen HNO-Kliniken nahmen 50 an der Umfrage teil (31,3%). Davon führten 76%...
Source: Laryngo- Rhino- Otologie - April 2, 2024 Category: ENT & OMF Authors: Deuss, Eric Becker, Sven Meyer, Moritz Hussain, Timon Eckrich, Jonas Lang, Stephan Klimek, Ludger Ernst, Benjamin Tags: Originalarbeit Source Type: research
Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry
Indobufen is widely used in patients with aspirin intolerance in East Asia. The OPTION trial launched by our cardiac center examined the performance of indobufen based dual antiplatelet therapy (DAPT) after pe... (Source: BMC Medicine)
Source: BMC Medicine - April 2, 2024 Category: Internal Medicine Authors: Chunfeng Dai, Muyin Liu, Zheng Yang, Youran Li, You Zhou, Danbo Lu, Yan Xia, Ao Chen, Chenguang Li, Hao Lu, Yuxiang Dai, Jianying Ma, Zhangwei Chen, Juying Qian and Junbo Ge Tags: Research article Source Type: research
Risk and Benefit of Secondary Prevention with Aspirin Versus P2Y12 Inhibitor in CAD Patients
Clinical question: In patients with coronary artery disease (CAD), what is the difference in risk and benefit between secondary prevention with aspirin (ASA) versus a P2Y12 inhibitor?
Background: Lifelong ASA is the mainstay of care for patients with CAD who require secondary prevention. This is predicated on studies from several decades ago. Subsequent studies examining P2Y12 monotherapy versus ASA have had inconsistent results.
Study design: Systematic review and meta-analysis
Setting: Seven randomized clinical trials from 1996 to 2021 were found to meet the criteria for analysis.
Synopsis: 24,325 patients were included ...
Source: The Hospitalist - April 1, 2024 Category: Hospital Management Authors: Ronda Whitaker Tags: Cardiology In the Literature Source Type: research
Aspirin in Patients with Viral Hepatitis: Systematic Review and Meta-Analysis of Observational Studies
ConclusionsOur meta-analysis shows that in patients with chronic viral hepatitis, aspirin use is associated with a significantly reduced risk of liver cancer, but attention should be paid to the possible risk of gastrointestinal bleeding, and this conclusion needs further validation in the future. (Source: Journal of Gastrointestinal Cancer)
Source: Journal of Gastrointestinal Cancer - April 1, 2024 Category: Cancer & Oncology Source Type: research
Assessment of Platelet Response to Aspirin Therapy and Hemocompatibility-Related Adverse Events in HeartMate 3 Left Ventricular Assist Device Recipients
Purpose: Patients receiving left ventricular assist devices (LVADs) typically undergo anticoagulation and aspirin (ASA) therapy. The HeartMate 3 (HM3) has shown promise in reducing hemocompatibility-related adverse events (HRAEs) like stroke, thrombosis and bleeding. However, it remains uncertain whether ASA responsiveness impacts the incidence of HRAEs and if ASA sensitivity changes during HM3 support. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , H. Al Asadi, T. Abart, C. Schwarz, H. Schima, J. Riebandt, C. Marko, D. Wiedemann, B. Messner, D. Zimpfer Source Type: research
Impact of Concomitant Surgical Procedures in a Randomized Controlled Trial of Aspirin Removal in Left Ventricular Assist Device Patients - An Analysis from The ARIES Trial
Purpose: ARIES is an international, placebo-controlled, study of aspirin (100mg daily) in patients implanted with the HM3 LVAD to demonstrate that elimination of aspirin from the antithrombotic regimen preserves safety and efficacy and reduces residual risk of non-surgical bleeding complications. The primary endpoint results of the ARIES HM3 Trial will be presented in November 2023. In this analysis, we seek to analyze the impact of concomitant procedures (stratified by valvular and non-valvular surgery) on hemocompatibility related outcomes within the study. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M.R. Mehra Source Type: research
A Comprehensive Analysis of Bleeding Outcomes with Aspirin Removal with a Fully Magnetically Levitated LVAD - The International Randomized Controlled ARIES Trial
Purpose: Although hemocompatibility related adverse events including pump thrombosis and stroke have been reduced with introduction of a fully magnetically levitated LVAD, the incidence of non-surgical bleeding remains high. Whether aspirin, as part of an antithrombotic regimen including Vitamin-K Antagonist (VKA) may be safely removed and if it reduces the residual risk of non-surgical bleeding complications remains unknown. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M.R. Mehra Source Type: research
Prevalence and Outcomes of Reduced Intensity Anticoagulation in Patients Supported with Left Ventricular Assist Devices
Purpose: Patients with ventricular assist devices (VAD) are typically treated with aspirin and warfarin, but some cannot tolerate full anticoagulation (AC). With the improved biocompatibility observed with a fully magnetically levitated centrifugal flow pump (HeartMate 3 [HM3] VAD), clinicians have more flexibility to reduce AC, reducing bleeding risk. However, limited information exists regarding outcomes in patients on reduced or no AC. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Shin, Q. Huang, S. Sudat, B. Sheridan Source Type: research
Impact of Vitamin K Antagonist Therapy on Outcomes in a Randomized Controlled Trial of Aspirin Removal in Left Ventricular Assist Device Patients - A Pre-Specified Analysis from The ARIES Trial
Purpose: ARIES is an international, placebo-controlled study of aspirin (100mg daily) in HM3 LVAD patients to test the hypothesis that elimination of aspirin from the anti-thrombotic regimen preserves safety and efficacy and reduces residual risk conferred by non-surgical bleeding complications. The primary endpoint results of the ARIES HM3 Trial will be presented in November 2023. In this pre-specified secondary analysis, we seek to analyze the impact of background vitamin K antagonist (VKA) therapy on hemocompatibility related outcomes. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M.R. Mehra Source Type: research
Impact of rise and fall phases of shear on platelet activation and aggregation using microfluidics
J Thromb Thrombolysis. 2024 Mar 31. doi: 10.1007/s11239-024-02968-1. Online ahead of print.ABSTRACTBlood flow disorders are often the result of the non-physiological narrowing of blood arteries caused by atherosclerosis and thrombus. The blood then proceeds through rising-peak-decreasing phases as it passes through the narrow area. Although abnormally high shear is known to activate platelets, the shear process that platelets undergo in small arteries is complex. Thus, understanding how each shear phase affects platelet activation can be used to improve antiplatelet therapy and decrease the risk of side effects like bleedi...
Source: Atherosclerosis - March 31, 2024 Category: Cardiology Authors: Xuemei Gao Tiancong Zhang Xiaojing Huang Xuanrong Huan Yuan Li Source Type: research
Impact of rise and fall phases of shear on platelet activation and aggregation using microfluidics
J Thromb Thrombolysis. 2024 Mar 31. doi: 10.1007/s11239-024-02968-1. Online ahead of print.ABSTRACTBlood flow disorders are often the result of the non-physiological narrowing of blood arteries caused by atherosclerosis and thrombus. The blood then proceeds through rising-peak-decreasing phases as it passes through the narrow area. Although abnormally high shear is known to activate platelets, the shear process that platelets undergo in small arteries is complex. Thus, understanding how each shear phase affects platelet activation can be used to improve antiplatelet therapy and decrease the risk of side effects like bleedi...
Source: Atherosclerosis - March 31, 2024 Category: Cardiology Authors: Xuemei Gao Tiancong Zhang Xiaojing Huang Xuanrong Huan Yuan Li Source Type: research
